New treatment targeting a specific protein to fight aggressive brain tumors.
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma
This study is looking for better ways to treat glioblastoma, a tough brain tumor, by creating new chemotherapy drugs that target a specific protein that helps the tumor resist treatment, with the hope of improving outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-10876254 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, the most aggressive type of brain tumor, which has a very low survival rate after standard treatments. The project aims to develop new chemotherapy agents that inhibit a protein called LonP1, which is overexpressed in glioblastoma and contributes to the tumor's resistance to treatment. By targeting this protein, the researchers hope to improve treatment outcomes for patients with glioblastoma. The approach includes both laboratory studies using cell cultures and animal models to validate the effectiveness of the new therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who have undergone standard treatments but are facing tumor recurrence.
Not a fit: Patients with other types of brain tumors or those who have not been diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially extending survival and improving quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting mitochondrial functions in cancer treatment, suggesting that this approach could be effective, although it is still considered novel for glioblastoma.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Bota, Daniela Annenelie — University of California-Irvine
- Study coordinator: Bota, Daniela Annenelie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.